Core Insights - Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor® SR (venlafaxine hydrochloride) as the first and only treatment option for adults with generalized anxiety disorder (GAD) in Japan, addressing a significant unmet medical need [1][2] - The approval is based on a Phase 3 clinical trial that demonstrated the superiority of Effexor® in reducing anxiety symptoms compared to placebo, achieving its primary objective at 8 weeks [2][4] - GAD affects approximately 7.6% of the general population in Japan, indicating a substantial market opportunity for Viatris [2][3] Company Strategy - The approval of Effexor® reflects Viatris' strategy to advance a differentiated and innovative portfolio in Japan, focusing on value-added therapies [2][4] - The company aims to leverage its strong infrastructure and expertise in central nervous system therapies to enhance patient access to this new treatment [2][4] Clinical Study Details - The Phase 3 study (Study B2411367) was a placebo-controlled, randomized, double-blind, multicenter trial that met all primary and secondary efficacy endpoints [2][4] - Effexor® was well tolerated, with low discontinuation rates due to treatment-emergent adverse events (TEAEs) [4] Market Context - GAD is a prevalent mental health condition that significantly impacts quality of life, with a lifetime prevalence of 2.6% in Japan according to the World Health Organization [3] - The introduction of Effexor® is expected to address the underdiagnosis of GAD in Japan, providing a much-needed treatment option [3]

Core Viewpoint - Viatris Inc. has filed applications for the approval of Effexor SR Capsules (venlafaxine hydrochloride) to treat generalized anxiety disorder (GAD) in Japan, addressing a significant unmet medical need as no other treatment is currently approved for this indication in the country [1][2]. Company Overview - Viatris Inc. is a global healthcare company that aims to bridge the gap between generics and brand-name medications, providing access to high-quality medicines for approximately 1 billion patients annually [7][8]. Clinical Study Results - A Phase 3 study (Study B2411367) demonstrated the superiority of venlafaxine's anxiolytic effects compared to placebo at 8 weeks, achieving statistical significance (p-value=0.012) and meeting all seven secondary efficacy endpoints [2]. - The results from this study, along with findings from a long-term extension study, were included in the applications submitted to the Ministry of Health, Labor and Welfare (MHLW) [2]. Market Context - In Japan, the World Health Organization reports that 2.6% of the population will experience GAD in their lifetime, with a recent study indicating a probable prevalence of 7.6%, suggesting that GAD may be significantly underdiagnosed [6][5]. - Outside Japan, Effexor is already approved for GAD in over 80 countries, while it is currently approved in Japan only for major depressive disorder [3].